Product Code: 5385
Global Pregnancy Medication Market is set to witness lucrative growth and record a sizeable valuation by 2032, owing to the surging incidences of nutritional deficiencies in expectant mothers. The increasing prevalence of deficiency diseases in pregnant women can be attributed to improper sanitation, lack of hygiene, poor dietary habits, and reproductive health. Lack of essential nutrients during pregnancy can lead to future complications such as anemia and neural tube birth defects.
Based on estimates by the World Health Organization (WHO), approximately 40% of pregnant women globally are anemic. Iron deficiency anemia during pregnancy can lead to preterm delivery, fetal growth restriction, low birth weight, maternal infection, and other complications. To avoid these complexities, doctors prescribe a complete course of antianemia drugs, creating new industry growth prospects.
The pregnancy medication market is segregated based on drug class, pregnancy stage, distribution channel, and region.
With respect to drug class, the vaccines segment is projected to showcase more than 13% CAGR between 2023 and 2032. Certain vaccines administered to ensure the healthy growth of the unborn are safe for pregnant women, propelling their sales throughout the projection period. Besides, these vaccines also protect expecting mothers from acquiring serious illnesses such as hepatitis, bolstering their adoption over the next eight years.
Regarding the pregnancy stage, the 3rd-trimester segment is poised to accumulate decent revenues and record a fair target valuation by 2032. The maturation and development of critical body parts of the fetus, such as the lungs, brain, and kidneys, takes place during this period, significantly increasing the mother's nutritional requirements. The 3rd-trimester of pregnancy is recognized by episodic constipation, heartburn, and other complications, driving the demand for optimal pregnancy medications.
Online pharmacies are expected to amass a noticeable market share and emerge as a prominent distribution channel through 2032. The accelerated consumer shift toward online pharmacies owing to the availability of attractive discounts and offers on a wide range of healthcare and nutritional products will drive segment gains between 2023 and 2032. The increasing popularity of eCommerce websites due to their ease of use and hassle-free doorstep delivery services may create favorable growth scenarios for the pregnancy medication industry.
The Latin America pregnancy medication market is speculated to depict over 12.5% growth rate from 2023 to 2032. The considerable rise in household incomes across developed economies such as Mexico and Brazil will positively influence the regional landscape over the forthcoming years. In addition, the rising awareness about several complications associated with pregnancy and ensuring a healthy pregnancy and post-pregnancy care will ultimately boost business growth.
Table of Contents
Chapter 1 Methodology & Scope
- 1.1 Market definitions
- 1.2 Base estimates and working
- 1.2.1 North America
- 1.2.2 Europe
- 1.2.3 Asia pacific
- 1.2.4 Latin America
- 1.2.5 MEA
- 1.3 Forecast calculations
- 1.4 Data validation
- 1.5 Data sources
- 1.5.1 Secondary
- 1.5.1.1 Paid sources
- 1.5.1.2 Public sources
- 1.5.2 Primary
Chapter 2 Executive Summary
- 2.1 Pregnancy medication industry 360 degree synopsis, 2018 - 2032
- 2.1.1 Business trends
- 2.1.2 Drug class trends
- 2.1.3 Pregnancy stage trends
- 2.1.4 Distribution channel trends
- 2.1.5 Regional trends
Chapter 3 Pregnancy Medication Industry Insights
- 3.1 Industry segmentation
- 3.2 Industry landscape, 2018 - 2032
- 3.3 Industry impact forces
- 3.3.1 Growth drivers
- 3.3.1.1 Growing incidence of complications during pregnancy
- 3.3.1.2 Significant benefits of dietary supplements in pregnancy
- 3.3.1.3 Rising awareness regarding pregnancy care
- 3.3.2 Industry pitfalls & challenges
- 3.3.2.1 Side effects and risks associated with the use of other medication
- 3.3.2.2 Declining birth rate across the world
- 3.4 Growth potential analysis
- 3.4.1 By drug class
- 3.4.2 By pregnancy stage
- 3.4.3 by distribution channel
- 3.5 COVID- 19 impact analysis
- 3.6 Comparative analysis of nutrition recommendations & daily dietary allowances for pregnant and non-pregnant women
- 3.7 Regulatory landscape
- 3.8 Porter's analysis
- 3.8.1 Bargaining power of suppliers
- 3.8.2 Bargaining power of buyers
- 3.8.3 Threat of new entrants
- 3.8.4 Threat of substitutes
- 3.8.5 Industry rivalry
- 3.9 PESTLE analysis
Chapter 4 Competitive Landscape, 2021
- 4.1 Introduction
- 4.2 Company matrix analysis, 2021
- 4.3 Strategy dashboard, 2021
Chapter 5 Pregnancy Medication Market, By Drug Class
- 5.1 Key segment trends
- 5.2 Antianemia
- 5.2.1 Market size, by region, 2018 - 2032 (USD Million)
- 5.3 Antacids
- 5.3.1 Market size, by region, 2018 - 2032 (USD Million)
- 5.4 Antiallergic
- 5.4.1 Market size, by region, 2018 - 2032 (USD Million)
- 5.5 Analgesics
- 5.5.1 Market size, by region, 2018 - 2032 (USD Million)
- 5.6 Antimicrobials
- 5.6.1 Market size, by region, 2018 - 2032 (USD Million)
- 5.7 Hormones
- 5.7.1 Market size, by region, 2018 - 2032 (USD Million)
- 5.8 Laxatives
- 5.8.1 Market size, by region, 2018 - 2032 (USD Million)
- 5.9 Vaccines
- 5.9.1 Market size, by region, 2018 - 2032 (USD Million)
- 5.10 Nutritional supplements
- 5.10.1 Market size, by region, 2018 - 2032 (USD Million)
- 5.10.2 Minerals
- 5.10.2.1 Market size, by region, 2018 - 2032 (USD Million)
- 5.10.3 Omega 3
- 5.10.3.1 Market size, by region, 2018 - 2032 (USD Million)
- 5.10.4 Folic acid
- 5.10.4.1 Market size, by region, 2018 - 2032 (USD Million)
- 5.10.5 Vitamins
- 5.10.5.1 Market size, by region, 2018 - 2032 (USD Million)
- 5.10.6 Multivitamins
- 5.10.6.1 Market size, by region, 2018 - 2032 (USD Million)
- 5.10.7 Others
- 5.10.7.1 Market size, by region, 2018 - 2032 (USD Million)
- 5.11 Others
- 5.11.1 Market size, by region, 2018 - 2032 (USD Million)
Chapter 6 Pregnancy Medication Market, By Pregnancy Stage
- 6.1 Key segment trends
- 6.2 1st trimester
- 6.2.1 Market size, by region, 2018 - 2032 (USD Million)
- 6.3 2nd trimester
- 6.3.1 Market size, by region, 2018 - 2032 (USD Million)
- 6.4 3rd trimester
- 6.4.1 Market size, by region, 2018 - 2032 (USD Million)
Chapter 7 Pregnancy Medication Market, By Distribution Channel
- 7.1 Key segment trends
- 7.2 Hospital pharmacy
- 7.2.1 Market size, by region, 2018 - 2032 (USD Million)
- 7.3 Retail pharmacy
- 7.3.1 Market size, by region, 2018 - 2032 (USD Million)
- 7.4 Online pharmacy
- 7.4.1 Market size, by region, 2018 - 2032 (USD Million)
Chapter 8 Pregnancy Medication Market, By Region
- 8.1 Key regional trends
- 8.2 North America
- 8.2.1 Market size, by country, 2018 - 2032 (USD Million)
- 8.2.2 Market size, by drug class, 2018 - 2032 (USD Million)
- 8.2.2.1 Market size, by nutritional supplements, 2018 - 2032 (USD Million)
- 8.2.3 Market size, by pregnancy stage, 2018 - 2032 (USD Million)
- 8.2.4 Market size, by distribution channel, 2018 - 2032 (USD Million)
- 8.2.5 U.S.
- 8.2.5.1 Market size, by drug class, 2018 - 2032 (USD Million)
- 8.2.5.1.1 Market size, by nutritional supplements, 2018 - 2032 (USD Million)
- 8.2.5.2 Market size, by pregnancy stage, 2018 - 2032 (USD Million)
- 8.2.5.3 Market size, by distribution channel, 2018 - 2032 (USD Million)
- 8.2.6 Canada
- 8.2.6.1 Market size, by drug class, 2018 - 2032 (USD Million)
- 8.2.6.1.1 Market size, by nutritional supplements, 2018 - 2032 (USD Million)
- 8.2.6.2 Market size, by pregnancy stage, 2018 - 2032 (USD Million)
- 8.2.6.3 Market size, by distribution channel, 2018 - 2032 (USD Million)
- 8.3 Europe
- 8.3.1 Market size, by country, 2018 - 2032 (USD Million)
- 8.3.2 Market size, by drug class, 2018 - 2032 (USD Million)
- 8.3.2.1 Market size, by nutritional supplements, 2018 - 2032 (USD Million)
- 8.3.3 Market size, by pregnancy stage, 2018 - 2032 (USD Million)
- 8.3.4 Market size, by distribution channel, 2018 - 2032 (USD Million)
- 8.3.5 Germany
- 8.3.5.1 Market size, by drug class, 2018 - 2032 (USD Million)
- 8.3.5.1.1 Market size, by nutritional supplements, 2018 - 2032 (USD Million)
- 8.3.5.2 Market size, by pregnancy stage, 2018 - 2032 (USD Million)
- 8.3.5.3 Market size, by distribution channel, 2018 - 2032 (USD Million)
- 8.3.6 UK
- 8.3.6.1 Market size, by drug class, 2018 - 2032 (USD Million)
- 8.3.6.1.1 Market size, by nutritional supplements, 2018 - 2032 (USD Million)
- 8.3.6.2 Market size, by pregnancy stage, 2018 - 2032 (USD Million)
- 8.3.6.3 Market size, by distribution channel, 2018 - 2032 (USD Million)
- 8.3.7 France
- 8.3.7.1 Market size, by drug class, 2018 - 2032 (USD Million)
- 8.3.7.1.1 Market size, by nutritional supplements, 2018 - 2032 (USD Million)
- 8.3.7.2 Market size, by pregnancy stage, 2018 - 2032 (USD Million)
- 8.3.7.3 Market size, by distribution channel, 2018 - 2032 (USD Million)
- 8.3.8 Italy
- 8.3.8.1 Market size, by drug class, 2018 - 2032 (USD Million)
- 8.3.8.1.1 Market size, by nutritional supplements, 2018 - 2032 (USD Million)
- 8.3.8.2 Market size, by pregnancy stage, 2018 - 2032 (USD Million)
- 8.3.8.3 Market size, by distribution channel, 2018 - 2032 (USD Million)
- 8.3.9 Spain
- 8.3.9.1 Market size, by drug class, 2018 - 2032 (USD Million)
- 8.3.9.1.1 Market size, by nutritional supplements, 2018 - 2032 (USD Million)
- 8.3.9.2 Market size, by pregnancy stage, 2018 - 2032 (USD Million)
- 8.3.9.3 Market size, by distribution channel, 2018 - 2032 (USD Million)
- 8.4 Asia Pacific
- 8.4.1 Market size, by country, 2018 - 2032 (USD Million)
- 8.4.2 Market size, by drug class, 2018 - 2032 (USD Million)
- 8.4.2.1 Market size, by nutritional supplements, 2018 - 2032 (USD Million)
- 8.4.3 Market size, by pregnancy stage, 2018 - 2032 (USD Million)
- 8.4.4 Market size, by distribution channel, 2018 - 2032 (USD Million)
- 8.4.5 China
- 8.4.5.1 Market size, by drug class, 2018 - 2032 (USD Million)
- 8.4.5.1.1 Market size, by nutritional supplements, 2018 - 2032 (USD Million)
- 8.4.5.2 Market size, by pregnancy stage, 2018 - 2032 (USD Million)
- 8.4.5.3 Market size, by distribution channel, 2018 - 2032 (USD Million)
- 8.4.6 Japan
- 8.4.6.1 Market size, by drug class, 2018 - 2032 (USD Million)
- 8.4.6.1.1 Market size, by nutritional supplements, 2018 - 2032 (USD Million)
- 8.4.6.2 Market size, by pregnancy stage, 2018 - 2032 (USD Million)
- 8.4.6.3 Market size, by distribution channel, 2018 - 2032 (USD Million)
- 8.4.7 India
- 8.4.7.1 Market size, by drug class, 2018 - 2032 (USD Million)
- 8.4.7.1.1 Market size, by nutritional supplements, 2018 - 2032 (USD Million)
- 8.4.7.2 Market size, by pregnancy stage, 2018 - 2032 (USD Million)
- 8.4.7.3 Market size, by distribution channel, 2018 - 2032 (USD Million)
- 8.4.8 Australia
- 8.4.8.1 Market size, by drug class, 2018 - 2032 (USD Million)
- 8.4.8.1.1 Market size, by nutritional supplements, 2018 - 2032 (USD Million)
- 8.4.8.2 Market size, by pregnancy stage, 2018 - 2032 (USD Million)
- 8.4.8.3 Market size, by distribution channel, 2018 - 2032 (USD Million)
- 8.4.9 South Korea
- 8.4.9.1 Market size, by drug class, 2018 - 2032 (USD Million)
- 8.4.9.1.1 Market size, by nutritional supplements, 2018 - 2032 (USD Million)
- 8.4.9.2 Market size, by pregnancy stage, 2018 - 2032 (USD Million)
- 8.4.9.3 Market size, by distribution channel, 2018 - 2032 (USD Million)
- 8.5 Latin America
- 8.5.1 Market size, by country, 2018 - 2032 (USD Million)
- 8.5.2 Market size, by drug class, 2018 - 2032 (USD Million)
- 8.5.2.1 Market size, by nutritional supplements, 2018 - 2032 (USD Million)
- 8.5.3 Market size, by pregnancy stage, 2018 - 2032 (USD Million)
- 8.5.4 Market size, by distribution channel, 2018 - 2032 (USD Million)
- 8.5.5 Brazil
- 8.5.5.1 Market size, by drug class, 2018 - 2032 (USD Million)
- 8.5.5.1.1 Market size, by nutritional supplements, 2018 - 2032 (USD Million)
- 8.5.5.2 Market size, by pregnancy stage, 2018 - 2032 (USD Million)
- 8.5.5.3 Market size, by distribution channel, 2018 - 2032 (USD Million)
- 8.5.6 Mexico
- 8.5.6.1 Market size, by drug class, 2018 - 2032 (USD Million)
- 8.5.6.1.1 Market size, by nutritional supplements, 2018 - 2032 (USD Million)
- 8.5.6.2 Market size, by pregnancy stage, 2018 - 2032 (USD Million)
- 8.5.6.3 Market size, by distribution channel, 2018 - 2032 (USD Million)
- 8.5.7 Argentina
- 8.5.7.1 Market size, by drug class, 2018 - 2032 (USD Million)
- 8.5.7.1.1 Market size, by nutritional supplements, 2018 - 2032 (USD Million)
- 8.5.7.2 Market size, by pregnancy stage, 2018 - 2032 (USD Million)
- 8.5.7.3 Market size, by distribution channel, 2018 - 2032 (USD Million)
- 8.6 Middle East & Africa
- 8.6.1 Market size, by country, 2018 - 2032 (USD Million)
- 8.6.2 Market size, by drug class, 2018 - 2032 (USD Million)
- 8.6.2.1 Market size, by nutritional supplements, 2018 - 2032 (USD Million)
- 8.6.3 Market size, by pregnancy stage, 2018 - 2032 (USD Million)
- 8.6.4 Market size, by distribution channel, 2018 - 2032 (USD Million)
- 8.6.5 South Africa
- 8.6.5.1 Market size, by drug class, 2018 - 2032 (USD Million)
- 8.6.5.1.1 Market size, by nutritional supplements, 2018 - 2032 (USD Million)
- 8.6.5.2 Market size, by pregnancy stage, 2018 - 2032 (USD Million)
- 8.6.5.3 Market size, by distribution channel, 2018 - 2032 (USD Million)
- 8.6.6 Saudi Arabia
- 8.6.6.1 Market size, by drug class, 2018 - 2032 (USD Million)
- 8.6.6.1.1 Market size, by nutritional supplements, 2018 - 2032 (USD Million)
- 8.6.6.2 Market size, by pregnancy stage, 2018 - 2032 (USD Million)
- 8.6.6.3 Market size, by distribution channel, 2018 - 2032 (USD Million)
- 8.6.7 UAE
- 8.6.7.1 Market size, by drug class, 2018 - 2032 (USD Million)
- 8.6.7.1.1 Market size, by nutritional supplements, 2018 - 2032 (USD Million)
- 8.6.7.2 Market size, by pregnancy stage, 2018 - 2032 (USD Million)
- 8.6.7.3 Market size, by distribution channel, 2018 - 2032 (USD Million)
Chapter 9 Company Profiles
- 9.1 F. Hoffmann-La Roche Ltd
- 9.1.1 Business overview
- 9.1.2 Financial data
- 9.1.3 Product landscape
- 9.1.4 Strategic outlook
- 9.1.5 SWOT analysis
- 9.2 Alkem Laboratories Limited
- 9.2.1 Business overview
- 9.2.2 Financial data
- 9.2.3 Product landscape
- 9.2.4 Strategic outlook
- 9.2.5 SWOT analysis
- 9.3 Piramal Enterprises Limited
- 9.3.1 Business overview
- 9.3.2 Financial data
- 9.3.3 Product landscape
- 9.3.4 Strategic outlook
- 9.3.5 SWOT analysis
- 9.4 Cipla Limited
- 9.4.1 Business overview
- 9.4.2 Financial data
- 9.4.3 Product landscape
- 9.4.4 Strategic outlook
- 9.4.5 SWOT analysis
- 9.5 Pfizer Inc
- 9.5.1 Business overview
- 9.5.2 Financial data
- 9.5.3 Product landscape
- 9.5.4 Strategic outlook
- 9.5.5 SWOT analysis
- 9.6 Dr. Reddy's Laboratories
- 9.6.1 Business overview
- 9.6.2 Financial data
- 9.6.3 Product landscape
- 9.6.4 Strategic outlook
- 9.6.5 SWOT analysis
- 9.7 Alembic Pharmaceuticals Ltd
- 9.7.1 Business overview
- 9.7.2 Financial data
- 9.7.3 Product landscape
- 9.7.4 Strategic outlook
- 9.7.5 SWOT analysis
- 9.8 Lupin Limited
- 9.8.1 Business overview
- 9.8.2 Financial data
- 9.8.3 Product landscape
- 9.8.4 Strategic outlook
- 9.8.5 SWOT analysis
- 9.9 Glenmark Pharmaceuticals Ltd
- 9.9.1 Business overview
- 9.9.2 Financial data
- 9.9.3 Product landscape
- 9.9.4 Strategic outlook
- 9.9.5 SWOT analysis
- 9.10 Viatris Inc. (Mylan Inc.)
- 9.10.1 Business overview
- 9.10.2 Financial data
- 9.10.3 Product landscape
- 9.10.4 Strategic outlook
- 9.10.5 SWOT analysis
- 9.11 Amgen Inc
- 9.11.1 Business overview
- 9.11.2 Financial data
- 9.11.3 Product landscape
- 9.11.4 Strategic outlook
- 9.11.5 SWOT analysis